Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...

French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the ...

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

With the peak flu season often occurring during December and January and even into February, Dr. Sharon Nachman, Chief of the ...

Sanofi (SNYNF, SNY) said it is shipping BEYFORTUS 50mg and 100mg Injection doses in the US to private healthcare providers and to the ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

Company planning for every eligible baby in the US to have access to BEYFORTUS <li /> New BEYFORTUS filling line approved by the ...

Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...